http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004092171-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cdf2f979e5acf092e39e451f0625d7ce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_143d69e07b1878f82392bc0ab11fac4d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aebba0e88df7e3a35163efe898481317
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e9c55cbd632f124625c19c848aaffd9c
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D519-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-06
filingDate 2004-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_586580640aa8229bdffddda5d992f35b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee93251d4794df556f5fbea1b4e8a1a8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d4267a0e2377ba1d7ac4df1cf9af556
publicationDate 2005-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2004092171-A3
titleOfInvention Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosin e receptor antagonists
abstract The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the A2a adenosine receptor, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including Parkinson's disease. In one embodiment, the invention features a compound of formula (I) .
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7197558-B2
priorityDate 2003-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0515107-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9943678-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419524544
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414804781
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393686
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID21964407
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419507710
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60961
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11636795

Total number of triples: 39.